Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1188320100040040466
Gut and Liver
2010 Volume.4 No. 4 p.466 ~ p.474
Helicobacter pylori Seropositivity Is Associated with Gastric Cancer Regardless of Tumor Subtype in Korea
Cho Soo-Jeong

Choi Il-Ju
Kim Chan-Gyoo
Lee Jong-Yeul
Kook Myeong-Cherl
Seong Moon-Woo
Park Sook-Ryun
Lee Jong-Seok
Kim Young-Woo
Ryu Keun-Won
Lee Jun-Ho
Nam Byung-Ho
Park Young-Iee
Abstract
Background/Aims: To evaluate the association between Helicobacter pylori (H. pylori) infection and gastric cancer (GC) according to tumor subtype in Korea.

Methods: H. pylori status was determined serologically using the enzyme-linked immunosorbent assay. In total, 2,819 patients with GC and 562 healthy controls were studied. A logistic regression method was used after adjusting for possible confounders.

Results: The prevalence of H. pylori infection was significantly higher in the GC patients (84.7%) than in the controls (66.7%) (odds ratio [OR], 3.13; 95% confidence interval [CI], 2.46-3.97). The adjusted OR was significantly higher in H.-pylori-infected patients aged ??60 years (OR, 4.69; 95% CI, 3.44-6.38) than in those aged ¡Ã60 years (OR, 1.48; 95% CI, 0.88-2.46; p??0.001). Subgroup analyses revealed no differences in seroprevalence between early gastric cancer (84.8%; OR, 3.01; 95% CI, 2.27-4.01) and advanced gastric cancer (84.6%; OR, 2.94; 95% CI, 2.24-3.85), cardia cancer (83.8%; OR, 2.98; 95% CI, 2.16-4.02) and noncardia cancer (84.8%; OR, 3.17; 95% CI, 2.48-4.04), and differentiated carcinoma (82.7%; OR, 2.99; 95% CI, 2.21-4.04) and undifferentiated carcinoma (86.8%; OR, 3.05; 95% CI, 2.32-4.00).

Conclusions: The seroprevalence of H. pylori was higher in GC patients than in healthy controls, especially in younger patients. H. pylori infection is associated with GC, regardless of the tumor location, stage, or differentiation.
KEYWORD
Helicobacter pylori, Gastric cancer, Prevalence, Odds ratio, Subgroup analysis
FullTexts / Linksout information
 
Listed journal information
SCI(E) MEDLINE ÇмúÁøÈïÀç´Ü(KCI) KoreaMed